Case ascertainment and estimated incidence of drug-induced long-QT syndrome: study in Southwest France by Molokhia, Mariam et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Case ascertainment and estimated incidence of drug-induced
long-QT syndrome: study in Southwest France
Citation for published version:
Molokhia, M, Pathak, A, Lapeyre-Mestre, M, Caturla, L, Montastruc, JL, McKeigue, P & L'Assoc Francaise
des Ctr Regionau 2008, 'Case ascertainment and estimated incidence of drug-induced long-QT syndrome:
study in Southwest France' British Journal of Clinical Pharmacology, vol 66, no. 3, pp. 386-395. DOI:
10.1111/j.1365-2125.2008.03229.x
Digital Object Identifier (DOI):
10.1111/j.1365-2125.2008.03229.x
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
British Journal of Clinical Pharmacology
Publisher Rights Statement:
Wiley online open article. Copyright © 2008 The Authors Journal compilation © 2008 Blackwell Publishing Ltd
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
Case ascertainment and
estimated incidence of
drug-induced long-QT
syndrome: study in
Southwest France
Mariam Molokhia1, Atul Pathak2, Maryse Lapeyre-Mestre2,
Laetitia Caturla2, Jean Louis Montastruc2, L’Association Française
des Centres Régionaux de Pharmacovigilance (CRPV)3 and
Paul McKeigue4
1Non-Communicable Disease Epidemiology UnitLondon School of Hygiene & Tropical MedicineKeppel
Street, WC1E 7HT London, UK
2Service de Pharmacologie Clinique du CHU de ToulouseCentre Midi-Pyrénées de Pharmacovigilance,
de Pharmacoépidémiologie et d’Informations sur le Médicament, EA 3696 Pharmacoepidemiology
unit, Université Paul Sabatier37 allées Jules Guesde, Toulouse, France
3Centre Régional de Pharmacovigilance, Hôpital Edouard Herriot – Pav N5, place d’Arsonval 69003 Lyon
4Public Health Sciences,The University of Edinburgh Medical School,Teviot Place Edinburgh EH8 9AG
Correspondence
Dr Mariam Molokhia, Non-Communicable
Disease Epidemiology Unit, London
School of Hygiene and Tropical Medicine,
Keppel Street, London WC1E 7HT, UK.
Tel:+44 0 207 927 2633
Fax:+44 0 207 580 6897
E-mail: mariam.molokhia@lshtm.ac.uk
----------------------------------------------------------------------
Keywords
arrhythmia, genetics, long-QT syndrome,
pharmacoepidemiology, torsade de
pointes
----------------------------------------------------------------------
Received
23 August 2007
Accepted
19 May 2008
Published OnlineEarly
16 July 2008
WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• Drug-induced long-QT syndrome (LQTS) is a
potentially fatal condition that has led to a
number of postmarketing withdrawals in
recent years.
• However, many cases may not survive long
enough to reach hospital, and only a small
proportion are reported to pharmacovigilance
agencies.
• The extent to which genetic determinants of
susceptibility to LQTS are specific to particular
drugs, or common to several classes of drug,
remains to be determined.
WHAT THIS STUDY ADDS
• We estimated population prevalence of
drug-induced LQTS in the Midi-Pyrenees
region, southwest France, using five different
institutions and assessed feasibility of tracing
potential cases (in addition to
pharmacovigilance data), using hospital data
and rigorous case definition.
• These methods can be adapted to a wider
region, used to augment pharmacovigilance
reporting, and offer researchers the
opportunity to study genetic susceptibility to
drug-induced LQTS.
AIMS
The aim of this study was to investigate the incidence and reporting rate of
drug-induced long-QT syndrome (LQTS) in France [defined by evidence of
torsades de pointes (TdP), QT prolongation and exposure to a relevant
drug] and to assess feasibility of case collection for drug-induced LQTS.
METHODS
A retrospective population-based study was carried out in Southwest
France in five institutions: three main hospitals, one private clinic and one
cardiac emergency unit, searched from 1 January 1999 to 1 January 2005
(population coverage of 614 000). The study population consisted of 861
cases with International Classification of Diseases-10 diagnostic codes for
ventricular tachycardia (I147.2), ventricular fibrillation (I149.0) and sudden
cardiac death (I146.1) from hospital discharge summaries, supplemented by
cases reported to national or regional pharmacovigilance systems, and
voluntary reporting by physicians, validated according to internationally
defined criteria for drug-induced LQTS.
RESULTS
Of 861 patients coded with arrhythmias or sudden cardiac death, there
were 40 confirmed surviving acquired cases of drug-induced LQTS. We
estimated that the incidence of those who survive to reach hospital
drug-induced LQTS is approximately 10.9 per million annually in France
(95% confidence interval 7.8, 14.8).
CONCLUSIONS
Many cases of drug-induced LQTS may not survive before they reach
hospital, as the reporting rate for drug-induced LQTS identified through the
cardiology records and also reported to pharmacovigilance systems for the
Midi-Pyrenees area is 3/40 (7.5%). Using the methods outlined it is possible
to assemble cases to study genetic susceptibility to drug-induced LQTS and
adapt these methods more widely.
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Introduction
Background
Relevance of studying the genetics of susceptibility to
drug-induced long-QT syndrome Drug-induced long-QT
syndrome (LQTS) has led to several postmarketing drug
withdrawals in the last decade [1]. These include drugs
such as thioridazine, levoacetylmethadone and astemizole,
after these drugs had been marketed for several years. In
patients treated with antipsychotic agents such as thior-
idazine and droperidol, asymptomatic lengthening of the
rate-corrected QT interval is common, and the risk of
sudden cardiac death has been shown to be increased
two-to-threefold [2, 3], but rarely appears on adverse drug
reaction (ADR) reports. Failure to appreciate the magni-
tude of risk may delay withdrawal of a drug. For example,
the eventual withdrawal of thioridazine in June 2005 was
many years after the association with LQTS had been
described, as the magnitude of the effect on sudden
cardiac death became clear. Cases present with syncope
and polymorphic ventricular tachycardia (VT) [torsades de
pointes (TdP)] and prolongation of the QT interval. LQTS is
likely to pass unrecognized as a cause of sudden cardiac
death, as the diagnosis is unlikely to be made unless cases
survive long enough to reach hospital.
Data from the World Health Organization Uppsala
Monitoring Centre (UMC) have shown that most sponta-
neous reports (>50%) of LQTS recorded in the different
pharmacovigilance systems in the world concern mainly
class III antiarrhythmics (sotalol, amiodarone), followed by
anti-infective drugs (macrolides, quinolones, imidazole
antifungal drugs) and antihistaminic drugs. There is also
evidence of a cumulative effect of ketoconazole or mac-
rolide antibiotics on risk of drug-induced LQTS and of
some antihistamines, especially diphenhydramine [4].
Although testing of new drugs for effect on the QT interval
is now mandatory, such tests may fail to detect drugs that
cause torsade in a small number of susceptible individuals.
In addition to the low number of cases detected, tech-
niques for detecting drug-induced LQTS are not always
relevant; there is a lack of sensitivity of these methods,
which include ECG measurement to Holter recording or
more sophisticated techniques (post processing of ven-
tricular repolarization). Using data from the UMC, DeBruin
et al. found a statistically significant association between
the risk of cardiac arrhythmia and sudden death and the
level of antihuman ether-a-go-go-related gene (hERG)
potassium channel activity of drugs [relative risk (RR) 1.93,
95% confidence interval (CI) 1.89, 1.98], although this did
not allow for confounders such as co-prescription of drugs,
hypokalaemia or comorbidity [5]. Currently, there is wide-
spread testing of new drugs for ability to block hERG
potassium channels, based on recommendations to assess
the risk of QTc-interval prolongation and TdP for noncar-
diovascular drugs [6, 7]. Current use of noncardiac QTc-
prolonging drugs in a Dutch population is associated with
increased risk of cardiac death, especially with antipsycho-
tics such as haloperidol, with highest reported risks in
women and recent starters of medication [8].
Feasibility studies – preliminary work
To collect large numbers of cases of LQTS a European col-
laboration is required, as no single country can generate
enough cases. We have therefore established a network
(EUDRAGENE) to establish a DNA case–control collection
for studying the genetic basis of susceptibility to various
classes of ADR, based on case ascertainment through the
pharmacovigilance system. For LQTS/TdP, however, it is not
feasible to ascertain cases through the pharmacovigilance
system as the reporting rate is too low. In France, for
example, which has one of the most well-organized phar-
macovigilance systems in Europe, the reporting rate is only
about 0.8 per million per year, and a pilot study has shown
that only one-third of these meet our strict case definition
for LQTS/TdP.
The only feasible method to ascertain large numbers of
cases is by a systematic search of discharge records from
many hospitals. This is laborious, because standard diag-
nostic coding of hospital discharges [International Classifi-
cation of Diseases (ICD)-9 or ICD-10] does not specifically
classify LQTS, and it is necessary to search all diagnostic
codes for ventricular arrhythmia and associated outcomes
such as ventricular fibrillation (VF) and sudden cardiac
death, combined with medical records in hospital as
described below.
Methods
Setting
A retrospective population-based study was carried out
in the administrative area of Midi-Pyrenees (Southwest
France) and specifically in three cities with a population
coverage of 614 000 (Toulouse, Montauban and Albi). The
study was done in four hospitals: the regional university
tertiary hospital, two main hospitals and one private clinic,
all with cardiology department and cardiac emergency
units. We searched from hospital medical information
system all cases hospitalized from 1 January 1999 to 1
January 2005, with ICD-10 diagnostic codes of VT (I147.2),
VF (I149.0) and sudden cardiac death (I146.1) in the dis-
charge summaries. Additional information from ECGs and
medical records was sought with the appropriate con-
sents, and all putative cases were validated according to
internationally defined criteria (Appendix 1).
This study was carried out with the approval of the
French Drug Agency (AFSSAPS) and with the ethical
approval of the regional committee for biomedical
research according to French law.The project also followed
guidelines from the ethical review board of the European
Drug-induced LQTS
Br J Clin Pharmacol / 66:3 / 387
Commission as part of the EUDRAGENE project (http://
www.eudragene.org), including informed patient consent
where relevant.
Source population: Toulouse, Albi and
Montauban
The population served by the Toulouse University Hospital
is about 540 000 (60% of the metropolitan area of
Toulouse).The public and the private hospital in Albi cover
about 50 000 inhabitants and the public hospital in Mon-
tauban approximately 24 000. From the hospital’s informa-
tion system, we obtained a list of 861 hospitalizations
during the period 1 January 1999 to 1 January 2005 with
the ICD-10 codes of interest, for whom we examined
medical files. We also used data recorded in the French
Pharmacovigilance database, in order to identify cases
spontaneously reported to the Midi-Pyrenees pharma-
covigilance centre (covering an area of 2.4 millions inhab-
itants). Letters of invitation were sent to the general
practitioners (GPs) of all patients eligible for study and
alive at the time of last entry in the case notes. All cases
identified via hospital databases were subsequently
reported to the regional pharmacovigilance centre,
according to the French guidelines for pharmacovigilance
reporting.
Case definition
Electronic discharge summaries were selected with ICD-10
diagnostic codes of VT and examined by the research team
to classify these records for confirmation of diagnoses in
patients aged 18 years. For these records, case notes
were retrieved and examined by the research assistant.
Copies were taken of any ECGs recorded during the hospi-
tal episode and any additional ECGs recorded on a previ-
ous occasion (before starting the drug) or subsequently
(after recovery). Mean QTc and RR intervals were measured
on these ECGs by a trained cardiologist for independent
verification of prolonged QT interval according to pre-
defined criteria (Appendix 1). A list of drugs known to
cause LQTS was adapted from the University of Arizona
Centre for Education and Research on Therapeutics (http://
www.torsades.org) and from the French system of phar-
macovigilance, specifically for drugs available in Europe or
for new drugs.
We supplemented the case collection that met the
strict definition with additional cases of torsade without
QT prolongation and cases not exposed to drugs, to allow
researchers to test at a later date whether associations
detected with drug-induced LQTS are also seen with tor-
sades without QT prolongation, or with cases not exposed
to drugs.
As LQTS is one of several predisposing factors for TdP,
all other potential causes were excluded by careful exami-
nation of medical records by a cardiologist at the time of
their hospital appointment. Examples of exclusion were:
structural cardiac diseases, metabolic abnormalities,
conduction defects, systemic diseases and hereditary dis-
turbances of the rhythm associated with sudden cardiac
death such as Brugada syndrome.
Comorbidities
Medical records were searched to examine comorbidities
for drug-induced LQTS. These included patients in whom
arrhythmia occurred only during acute coronary ischaemia
(supported by ECG changes or elevated cardiac enzymes)
or within 3 months of an acute coronary event, and
diagnosed cases of Mendelian forms of LQTS, who were
excluded from the study. We also collected electrolyte
data and excluded cases with abnormal potassium levels
(3.5 mmol l-1 or5.5 mmol l-1). Data were also collected
on use of co-medication at the time of the event.
Statistical analyses
Analyses were conducted using STATA version 9 (STATA
Corp., College Station, TX, USA). The incidence of nonfatal
drug-induced LQTS was calculated by the ratio of events
per year divided by 1 000 000 population, based on the
coverage area of the hospitals and centres involved, with
95% CI assuming a Poisson distribution. The denominator
over the time of the study was approximately 3.68 million
patient-years. We did not calculate specific incidences for
separate drug classes due to the small numbers involved,
although approximately 50% of cases were taking antiar-
rhythmic medication.
Results
Among the total of 861 cases diagnosed as ‘ventricular
tachycardia’, 628 (73%) were male; of those diagnosed pre-
sumed alive with possible torsades, without conduction
defect, atrial fibrillation or myocardial infarction, from data
available, 25/49 (51%) cases were female and 24/49 (49%)
were male (P < 0.001). For four men and two women the
diagnosis of torsades could not be confirmed as medical
notes were incomplete. (One man was not known to be
taking any medication.) The flowchart (Figure 1) gives
further breakdown of the excluded cases. From 99 dead
cases diagnosed as VT, cause of death was listed in 29/99
(29%) cases as: cardiorespiratory arrest (n = 8), cardiogenic
shock or insufficiency (n = 6),TdP and VT, other arrhythmias
(n = 7) (there was no mention of LQTS in any of the causes
of death) and death from natural causes (n = 5), sudden
death (n = 1), cerebrovascular haemorrhage (n = 1) and
septicaemia (n = 1). All cases were of European ethnicity. In
surviving patients the mean age for men was 72.7 (SD 18.2,
range 22–106 years) and for women 78.3 (SD 24.1, range
15–106 years). From Toulouse, Montauban, Albi and the
pharmacovigilance database, for 56 of the cases alive clas-
sified as ‘possible acquired LQTS or torsades’, 36 case notes
or ADR reports were successfully retrieved to date. Of 56
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presumed live cases documented as either torsades or
LQTS, replies or medical files were unavailable from doctor
for 11 patients, nine patients refused or were medically
unfit to participate (of these, four were confirmed TdP/
LQTS) and nine patients or their doctors were untraceable
(of these, data were incomplete for six; three were con-
firmed TdP/LQTS). For the untraceable/unavailable cases
for which further information was obtained, seven names
of the reporting doctors were not available (anonymized
by pharmacovigilance centre), one report did not contain
the doctor’s name, one patient had left for a convalescent
home and one patient was no longer in contact with their
GP. Of the remaining 40 confirmed traceable cases, 28
(70%) had prolonged QTc measured on ECG (together with
VT or VF), 30 (75%) had syncope with documented prema-
ture ventricular contractions, and 24 (60%) LQTS and
torsades measured on ECG (mean QTc 547 ms, SD 105).
Twenty-four patients agreed to take part and donated
blood samples for which genetic analyses are planned at a
later date. For those on whom drug information was avail-
able (surviving and dead cases), 21/55 (38%) were taking
amiodarone (including amiodarone combinations), and
19/55 (35%) suspected cases were taking a combination of
two or more drugs known to cause LQTS. All cases ascer-
tained through pharmacovigilance systems were also
identified from hospital records.
From the centres selected in the Midi-Pyrenees area, 40
confirmed cases of nonfatal torsades with QT prolonga-
tion, excluding those with other causes of VT, such as
underlying heart disease or Mendelian syndromes, were
included in the study. In a population of 614 000 over 6
years, we estimate the incidence of diagnosed nonfatal
torsades as around 10.9 per million per year (95% CI 7.8,
14.8). We estimate that, with the strict definition of LQTS
that we are using, 98% of cases without underlying heart
disease have been exposed to a relevant drug. Results for
Toulouse, Albi, Montauban and the pharmacovigilance
database, Midi-Pyrenees area are presented in the flow-
chart (Figure 1).
Discussion
Ascertainment of cases
This study has a response rate of 60% of those confirmed
eligible. Other studies that have attempted to contact
cases of drug-induced LQTS have had much lower
response rates (<10%) [9] and illustrate difficulties of con-
tacting physicians and patients. It is not possible to contact
patients directly without the consent of their physician or
GP, although almost all of the physicians contacted agreed
to participate. This study did not examine fatal cases of
drug-induced LQTS, although this would be possible pro-
vided the diagnoses could be confirmed from the medical
records.
Incidence of TdP/LQTS
From data from hospital and clinic discharge summaries in
France we estimate the true incidence of torsades/LQTS to
be around 5–7% of cases diagnosed as ‘ventricular tachy-
cardia’, ‘ventricular fibrillation’ or ‘sudden cardiac death’,
excluding acute coronary syndromes or congenital LQTS.
Although the methodology for case ascertainment used
ICD-9 or -10 coding, all potential cases were subjected to
a rigorous medical record and ECG review by a trained
cardiologist, based on internationally defined criteria for
drug-induced LQTS and TdP (Appendix 1).
Our study showed women have a greater susceptibility
to TdP in drug-induced LQTS than men (51% vs. 49%),
which is consistent with other studies and thought possi-
bly to be due to regulation of ion channel by sex hormones
[10]. Extrapolating from the Toulouse, Albi and Montauban
coverage areas, we estimated the incidence of torsades
(both sexes) using definite medical record/ECG confirma-
tion to be approximately 10.9 per million per year (95% CI
7.8, 14.8). This is comparable to the estimate of 40 per
million per year, excluding acute ischaemic-related cases
(derived 95% CI 21.9, 67.1) obtained in a Swedish study
(Medical Products Agency), in which cases of torsades were
notified prospectively by cardiologists [11]. However, the
Swedish study included fatal and nondrug-induced cases.
It should be noted, however, that this estimate was based
on 14 cases of TdP and data extrapolated from a 28-day
study period, which may result in some uncertainty around
the accuracy of these estimates. If drug-induced cases
represent 10/14 torsades cases [11], this would give an
incidence in Sweden of approximately 30 per million
year-1. Table 1 compares European reporting rates for TdP/
LQTS using pharmacovigilance data.
In France it is clear that this is likely to be an under-
estimate of true LQTS cases, as many cases will not sur-
vive before they reach hospital. These differences may
also reflect different prescribing practices in France and
Sweden. A recent amiodarone drug utilization study in our
area found no difference in the use of this drug according
to gender [12].
From this study, searches from the three main general
hospitals and clinics serving about 614 000 people in Tou-
louse, Albi and Montauban yielded 861 discharge records
coded as ventricular arrhythmia in the last 6 years. It is
possible that the potential source population may actually
be slightly higher (due to possible referrals to city hospitals
from rural areas), but we do not expect this would affect
our result greatly. Of these, about 40 were identified as
possible cases of drug-induced LQTS on the basis of infor-
mation in the cardiology discharge summary satisfying
inclusion criteria (ECGs and cardiologist discharge letters
searched electronically to confirm diagnosis or exclude
unlikely cases). Of these, about 30 were alive and eligible
for study, and 24 of these responded to invitation. Collec-
tion of 600 cases will thus require searching 100 public
hospitals across France.
Drug-induced LQTS
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Table 2 shows categorization of possible torsades
cases. Of people alive included in the study with drug-
induced torsades and available ECGs or data from ECG
recordings, mean QTc was 547 ms, SD 105. Differences
in the cut-off criteria for prolonged QT interval or cor-
rection used made very little difference to the overall
result. Only two cases had documented LQT without
torsades.
Most LQTS cases are taking class 3 antiarrhythmic drugs
or b-blockers, with very few on antipsychotic (one case
with possible torsades) or antibiotic drug classes (Table 3).
It is unclear whether low rates of torsades associated with
antipsychotic drugs are due to lower prescribing rates of
drugs such as thioridazine (discontinued from June 2005)
following changes in prescribing as seen in the UK [13], or
high case fatalities associated with these drugs.Prescribing
data from France suggest that rates of antipsychotic reim-
bursement have decreased over recent years (Figure 2),
which could reflect lower prescribing rates [14]. However,
French national sales data for diuretics, b-blockers and
antiarrhythmic drugs are relatively stable (http://
afssaps.sante.fr/pdf/5/rapmed05.pdf ).
Coded ventricular arrhythmia, 
including ventricular fibrillation 
or sudden cardiac death 861 
No ventricular tachycardia 
(AF, TIA) 143/861 (16.6%)
Not arrhythmia 50/346 
(14.5%)
Myocardial infarction 
194/861 (22.5%)
Confirmed torsade  and QTc 
(EUDRAGENE criteria-
Appendix 1) 106/346 (30.6%) 
Congenital  LQT 
50/101(49.5%)
Possibly acquired* 
56/106 (52.8%)
No medical file 11/56 
(19.6%)
Torsade & LQTS confirmed 
with or without drug exposure 
36/56 (64.3%)
Patient/doctor refused/ 
unfit 9/56 (16.1%; 4 
confirmed TdP/LQTS) 
Total confirmed 40; Sampled 
24/40 (60 %)
VT possible without MI 
346/861 (40.2%)
Conduction 
defect/ventricular dysplasia 
57/861 (6.6%)
Patient or doctor 
untraceable 9/56 (16.1%;
3 confirmed TdP/LQTS) 
Torsades alone 3/56 
(5.4%)
Cardiomyopathy/cardiac 
failure 22/ 861 (2.6%) 
Not LQT/other cause 
190/ 346 (54.9%)
Dead
99/861 (11.4%) 
Figure 1
Flowchart of case ascertainment in Toulouse, Albi, Montauban and pharmacovigilance database, Midi-Pyrenees area
M. Molokhia et al.
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The pharmacovigilance system has a much lower yield
of drug-induced LQTS/TdP; pharmacovigilance reports
estimated a total of 245 cases over 5 years, i.e. around 0.8
per million per year. In comparison with other ADRs, the
reporting rate for drug-induced LQTS/TdP is low, as many
cases will result in a fatal outcome that may not be attrib-
utable to the drug as they will not reach hospital.
Drug classes associated with LQTS
The website lists all drugs currently acknowledged to be
associated with acquired LQTS (http://www.eudragene.
org). Most cases are attributed to sotalol and amiodarone-
Table 1
European annual reporting rates for torsades de pointes/long-QT
syndrome (TdP/LQTS) per 10 million total population from pharmacovigi-
lance data
Country TdP LQTS
France 4.2 3.9
Belgium 2 2.8
Germany 1.3 1.3
Sweden 12
Spain 0.75 0.95
Italy (three regions) 0.11 0.66
Table 2
Categorization of 40 cases confirmed as ‘Possible alive torsades cases without conduction defect, atrial fibrillation or myocardial infarction’ with records
available (hospitals in Toulouse, Montauban, Albi and pharmacovigilance database, Midi-Pyrenees area)
Categories (documented by discharge summaries, medical
records or ECG) No. (%)
Prolonged QTc
documented in records QTc measured on ECG
Possible TdP/LQTS* – all 40 28 (70%) 24 (60%)
Polymorphic ventricular tachycardia or fibrillation (PVT)† 19 11 (58%) 9 (47%)
*Possible torsades is syncope plus either premature ventricular contraction or PVT plus LQT.
†Documented in medical records or on ECG recording.
Table 3
Data on drugs taken in all patients diagnosed with ‘Ventricular arrhythmia or sudden cardiac death’ and ‘all possible torsades without conduction
defect/atrial fibrillation or myocardial infarction’
Drug class
Possible torsades
(PVT or syncope
and PVC) + LQT
Coded ‘ventricular
arrhythmia or sudden
cardiac death’
Class III antiarrhythmics
Amiodarone 10 58
Amiodarone combinations 11 11
b-Blocker (sotalol; acebutolol, atenolol, bisoprolol) 8 22
b-Blocker combinations 3 3
Other cardiovascular drugs:
Digoxin 2 6
Digoxin combinations digoxin + flecainide or disopyramide (Class 1 antiarrhythmic) 2 2
ACE/ACE inhibitor + diuretic (benazepril + hydrochlorothiazide) 2 2
Class 1 antiarrhythmic (flecainide quinidine/hydroxyquinidine) 3 11
Class 1 antiarrhythmic combinations 1 1
Calcium channel antagonist (bepridil) 2 2
Other antihypertensives: vincamine (alkaloid), urapidil, alphagan (a-blocker) 1 3
Diuretic-(furosemide) 0 1
Other drugs:
H1 antihistamine (alimemazine) 0 1
Anti-infectious drugs (clofamizine, lomefloxacine, itraconazole) 2 4
COX-2 inhibitor (celecoxib) 1 1
Neuroleptics (amisulpride, thiorazidine, periciazine) 1 8
Antiepileptic (sodium valproate) 1 1
SSRI antidepressant (fluvoxamine) 0 1
Benzodiazepine 1 1
No drug 1 1
Data unavailable or not requested as other exclusion criteria 3 721
Total 55 861
PVC, premature ventricular contraction; PVT, polymorphic ventricular tachycardia; ACE angiotensin converting enzyme; COX, cyclooxygenase; SSRI, selective serotonin reuptake
inhibitor.
Drug-induced LQTS
Br J Clin Pharmacol / 66:3 / 391
like compounds, although in recent years amiodarone has
tended to replace quinidine. b-Blockers may also identify
patients with underlying cardiovascular disorder such as
hypertension and angina, which may interact to promote
drug-induced long QT due to co-prescriptions. For the
cases collected, data were recorded on co-prescribed
medication where available.
A few drugs implicated in drug-induced LQTS were
prescribed as combinations [e.g. angiotensin converting
enzyme inhibitor and diuretic (benazepril & hydrochlo-
rothiazide)], where it is possible that LQTS was secondary
to diuretic-induced hypokalaemia (data were unavailable
from the records). One individual not previously known
with congenital LQTS had non drug-associated LQTS that
was unexplained by other factors.
Ways to improve case ascertainment
One of the main problems in detecting cases of drug-
induced LQTS is that there is no specific ICD-10 code and
that cases could be coded otherwise in relationship to
associated disease or complication. A revision of ICD-10
codes to include a separate category for drug-induced
LQTS/TdP would enhance sensitivity of searches, prior
to validation by internationally defined criteria
(Appendix 1).
The average population coverage of such hospitals
varies between 50–300 000. In France and other European
countries, hospital discharge records are coded for
multiple diagnoses according to ICD-9 or -10 (Belgium,
Sweden, France, UK, the Netherlands, Spain, Italy and
Ireland). In principle, this approach can be extended to
each hospital, searching the database of hospital dis-
charges during the last 5 years to retrieve all records with
any of the following diagnostic codes, excluding records
with additional codes for acute coronary episodes such as
myocardial infarction.
National pharmacovigilance data and
cardiology networks; other data sources
Where possible, pharmacovigilance data from other
centres were used to identify further possible cases of
drug-induced LQTS/TdP, some of whom have already
agreed to participate in the study. Although numbers are
small, the sensitivity rates of cases identified in this manner
is high.
Cardiology networks and other centres specializing in
arrhythmias in France may aid further recruitment. Revi-
sion of hospital databases to allow drugs on admission to
be linked to text of discharge summary would help iden-
tify further cases. Computer programs able to search
free text of discharge letters would also help in improving
search strategies. In several European countries, there
are databases covering many general practices that
link clinical diagnoses to drug prescription records. In
some of these databases, such as NIN-GP (the Nether-
lands), diagnostic information is stored as free text
(rather than only as diagnostic codes). However, as the
total coverage of these databases is only a few million
people, they can contribute only a small proportion of
cases.
Summary
Many cases of drug-induced LQTS may not survive until
they reach hospital, therefore it is likely that there is
under-reporting of LQTS by cardiologists and other
medical staff to pharmacovigilance agencies. Ascertaining
cases from hospitals can be used to supplement pharma-
covigilance reporting for LQTS. Our estimate of drug-
induced LQTS in France (10.9 per million per year, 95% CI
7.8, 14.8), ascertained from hospital discharge summaries
and confirmed by medical records, will be an underesti-
mate of the true incidence as we did not include fatal
cases or cases for whom we were unable to trace records.
This study has shown a feasible method of ascertaining
potential cases of LQTS (in addition to pharmacovigilance
data), using hospital data and rigorous case definition
that can be adapted to a wider region, and offers
researchers the opportunity to study genetic susceptibil-
ity to drug-induced LQTS.
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Appendix 1: Case definition
For each suspected case, each of the criteria listed below
will be scored
V Polymorphic ventricular tachycardia (3 beats at
rate >100 min-1) or ventricular fibrillation, docu-
mented by an ECG recording or statement in the
case record
S Syncope recorded in case notes, and polymorphic
ventricular premature contractions documented
by an ECG recording in the case record
Q ECG recording during admission showing Fridericia
rate-corrected QT interval (QT/RR1/3) >440 ms in
men or >450 ms in women.
D Exposure (within an interval short enough for the
drug to be present) to a drug known to cause LQTS
(based on the drugs listed as causes of torsades,
supplemented with other drugs available in
Europe, http://www.torsades.org)
C Acute coronary ischaemia (supported by ECG
changes or elevated cardiac enzymes) in last 3
months or other underlying heart disease
M Diagnosed as congenital LQTS
Probable drug-induced LQTS is defined as
[(V or S) and* Q] and D and [not (C or M)]
This follows the definition for ‘high confidence in drug-
induced LQTS diagnosis’ given by Barbey, Lazzara and
Zipes [15] (http://www.arizonacert.org/medical-pros/
class-cases.htm). Although the reliability of measurement
of the rate-corrected QT interval based on a single ECG
recording is limited [16], the criterion chosen is sufficiently
stringent to be specific.
The diagnosis of drug-induced LQTS will be excluded
where an ECG taken before exposure to the suspected
drug shows a normal QT interval, or an ECG taken after an
interval long enough for the drug to be cleared shows that
the QT interval is still prolonged.
Torsades without structural heart disease is defined as
(Polymorphic ventricular tachycardia documented by ECG)
and [not (C or M)]
Appendix 2: Genetics of LQTS
Genetics of susceptibility to drug-induced LQTS
Research on genetic susceptibility to drug-induced LQTS
has focused mainly on genes that cause Mendelian forms
of the syndrome, and on genes that influence drug
metabolism, notably CYP2D6 and CYP3A4, which is inhib-
ited by drugs including macrolide antibiotics and imida-
zole antifungals. Six genes in which mutations cause
Mendelian forms of LQTS have been identified by family
linkage studies (Table 4): five encoding potassium chan-
nels (KCNQ1 on chromosome 11p, KCNH2 on chromosome
7q, KCNE1 and KCNE2 on chromosome 21q, KCNJ2 on chro-
mosome 17q) and one encoding a sodium channel (SCN5A
on chromosome 3p). Another locus (LQT4) causing a sub-
phenotype of LQTS has been mapped to chromosome 4q
and recently sequenced by Mohler et al., who identified
the underlying defect as a glu1425-to-gly (E1425G) mis-
sense mutation in the ankyrin-B gene [17], although this
may represent a clinical entity distinct from classic LQTS;
prolonged rate-corrected QT interval is not a consistent
feature and the identified protein is not an ion channel or
channel subunit. It has been suggested that the syndrome
previously ‘LQT4’ be renamed as ‘sick sinus syndrome asso-
ciated with bradycardia’ [18].
KCNQ1 is the commonest variant on congenital LQT
syndrome, of which there are two forms: Romano Ward is
the autosomal dominant form; and Jervell Lange-Nielsen
(KCNQ1/KCNE1) is an autosomal recessive/compound het-
erozygote that is associated with deafness, and is particu-
larly common in Norway. KCNJ2, known as the Anderson
syndrome, may represent a subtype, as often these cases
show different ventricular arrhythmias from types 1–6 [19].
Total prevalence at birth of these Mendelian syn-
dromes is estimated as 1–2 per 10 000. Not all individuals
who bear disease-causing mutations are affected, suggest-
ing that the effects of these genes depend upon other
‘modifier’ loci. Although patients with Mendelian forms of
LQTS are susceptible to drug-induced arrhythmias, mis-
sense mutations in genes that cause these Mendelian
syndromes are uncommon in patients with drug-induced
Table 4
Known genes associated with long-QT syndrome [Online Mendelian
Inheritance in Man (http://www.ncbi.nlm.nih.gov)]
Linkage Gene Chromosome
LQT1 KCNQ1 (KvLQT1) 11
LQT2 KCNH2 (hERG) 7
LQT3 SCN5A 3
LQT4 ANK2, GLU1425GLY 4
LQT5 KCNE1 21
LQT6 KCNE2 21
LQT7 KCNJ2 17
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long QT [20].A study looking at three congenital mutations
in LQT1-3 showed DNA variants in coding regions of these
genes can only be identified in 10–15% of acquired (drug-
induced) LQTS [21]. A recent study identifying cases of
drug-induced QTc prolongation and cardiac arrest in the
Netherlands screened 4/45 eligible cases for genetic muta-
tions and identified variants in KCNH2, SCN5A and KCNE1
[9].
Studying the genetic basis of susceptibility to drug-
induced LQTS may allow development of tests to identify
susceptible individuals, and may also identify target pro-
teins against which molecules can be screened to exclude
those that are likely to cause LQTS or even to develop novel
antiarrhythmic agents. The extent to which genetic deter-
minants of susceptibility to LQTS are specific to particular
drugs, or common to several classes of drug, remains to be
determined.
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